Hematology Special Issue (February) 2021 | CURE

February 28, 2021

It’s always best to have a team of people, whether friends or family, rooting us on as we face whatever challenges come our way.

February 27, 2021

Over the past decade, advances in both diagnostics and therapeutics in a variety of blood cancers have turned certain diseases into chronic conditions.

February 22, 2021

Patients with chronic myeloid leukemia are living longer, some even stopping treatment, thanks to a plethora of targeted therapies.

February 20, 2021

As part of its Speaking Out video series, CURE® spoke with Dr. Steven M. Horwitz on behalf of the Cutaneous Lymphoma Foundation about cutaneous T-cell lymphoma and options for treatment.

February 19, 2021

Oncologists and researchers are racing to identify new therapies to help better treat a rare form of acute lymphoblastic leukemia.

February 16, 2021

A meta-analysis found that minimal residual disease positivity after a particular treatment for mantle cell lymphoma can predict worse survival benefit.

February 15, 2021

The NCCN has updated its recommendations for chronic lymphocytic leukemia and small lymphocytic lymphoma to now include Brukinsa as a first- and second-line therapy in a subgroup of patients.

February 12, 2021

Blood shortages during the COVID-19 pandemic have forced cancer centers to get creative to ensure patients with hematologic malignancies are able to get transfusions in a timely manner.

January 05, 2021

Navigating the scary path of a cancer caregiver possibly becoming the patient with cancer.

December 21, 2020

This treatment strategy contributed to a median progression-free survival of 13.93 months compared with 9.46 months in those treated with Velcade and dexamethasone.

December 05, 2020

Five patient advocates, two oncologists and one caregiver were honored during CURE®’s eighth annual MPN Heroes Program.